Orally administered lanthanum carbonate (Fosrenol®) dissociates in the acid environment of
the upper gastrointestinal tract to release the cation lanthanum, which then binds dietary …

Abstract▴ Lanthanum carbonate is a novel, non-aluminium, non-calcium phosphate binding
agent that forms a water-insoluble compound, lanthanum phosphate, in the gut.▴ …

Patients with progressive chronic kidney disease (CKD) commonly develop mineral and
bone abnormalities and extraskeletal calcifications with following increased cardiovascular …

Background. The majority of patients with end-stage renal disease on dialysis are
hyperphosphataemic. Lanthanum carbonate has been shown to be a highly effective …

Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile
of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD). Data …

Lanthanum carbonate is considered to be the most potent of a new generation of
noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease …

Controlling hyperphosphatemia in patients with chronic renal failure on renal dialysis is a
major problem. None of the available calcium-or aluminum-based phosphate binders match …

Background Lanthanum carbonate is a highly effective phosphate binder with significant
potential as a treatment for hyperphosphatemia in patients with end-stage renal disease …

Background: Lanthanum carbonate, a new phosphate binder, is effective in reducing serum
phosphorus levels in patients with end-stage renal disease. A 1-year extension study to two …

Lanthanum carbonate is a non‐calcium‐based phosphate binder for hyperphosphatemia in
patients with chronic kidney disease (CKD). The efficacy and safety of lanthanum carbonate …